NKTR -102
文章来源:
hydrocortisone
于
2015-02-25 23:33:23
"We were encouraged to find that the CTC sub-study confirmed the presence of several potential target-specific pharmacodynamic biomarkers, such as topoisomerase 1, in the patients enrolled in our study," said
Ivan Gergel
, MD, senior vice president drug development and chief medical officer of
Nektar Therapeutics
. "The analysis from the BEACON CTC sub-study could help us better understand which additional patient populations would benefit from NKTR-102. We expect topline results from the BEACON study to be available in the first quarter of 2015."
